Antengene announces inclusion of XPOVIO® treatment in MM guidelines

Antengene Corporation Limited has reportedly announced the inclusion of Selinexor (XPOVIO®) treatment in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China.

This is the first time that XPOVIO® has been incorporated into the guidelines.

The 2022 guidelines were jointly revised by the Chinese Society of Hematology of the Chinese Medical Association (CMA) and the Chinese Hematology Association of the Chinese Medical Doctor Association (CMDA) and were issued in the Chinese Journal of Internal Medicine in May this year.

According to Professor Jin Lu from Peking University People's Hospital, the aging population is one of the reasons for the growing prevalence of MM in China.

Prof. Lu added that Selinexor was jointly approved by the CMA and CMDA in the guidelines, which indicates a strong acknowledgment of Selinexor's therapeutic utility in treating Myeloma.

The MM guidelines included four regimens of Selinexor combination therapy comprised of Selinexor and other chemotherapy or biological agents.

Recommendations for treating R/R MM (relapsed/refractory MM) are based on several medical evidential sources. This includes a patient’s response to previous treatment.

Being one of China’s most recognized guidelines, these are widely accepted by Chinese oncologists who adopt them in their clinical practice.

Dr. Jay Mei, Founder, CEO, and Chairman of Antengene expressed that the inclusion of Selinexor in the guidelines is crucial as it reinforces the clinical evidence supporting the usage of Selinexor in R/R MM patients from the first relapse through the complete progressions of disease.

Dr. Mei believes that the inclusion into MM guidelines in combination with robust clinical data will facilitate practitioners to adopt Selinexor into patient care thus benefitting R/R MM patients from this advanced therapy.

For those unversed, Selinexor is the first oral XPO1 inhibitor that received approval from the U.S.  FDA (Food and Drug Administration) for treating R/R MM (relapsed/refractory multiple myeloma) and R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

Source credit: